Leuprolide Research Dosage: Published Protocol Reference
Leuprolide dosage references vary by route and study context. The database lists Intramuscular or subcutaneous depot: 7.5 mg (monthly), 22.5 mg (3-month), 30 mg (4-month), 45 mg (6-month), Per depot interval, Subcutaneous (daily): 1 mg/day, Daily, and Subcutaneous implant: 65 mg, Every 12 months. These are research-context references, not a universal protocol.
Direct Answer
Leuprolide (Lupron) is FDA-approved for prostate cancer, endometriosis, uterine fibroids, and precocious puberty - one of the broadest indication profiles of any peptide drug in this library. With 40+ years of clinical use and extensive Phase 3 data across multiple indications, it is the reference GnRH agonist. A highly validated compound by any standard.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Sexual Health
- Best for
- Prostate cancer hormone therapy, endometriosis, uterine fibroids, precocious puberty, GnRH agonist reference compound
Research Dosage References
- <strong>Intramuscular or subcutaneous depot</strong> - 7.5 mg (monthly), 22.5 mg (3-month), 30 mg (4-month), 45 mg (6-month) - Per depot interval - Lupron Depot formulation. Injection by healthcare provider. Anti-androgen cover for first 2-4 weeks in prostate cancer to prevent flare.
- <strong>Subcutaneous (daily)</strong> - 1 mg/day - Daily - Used in IVF protocols and some pediatric applications. Less common than depot formulations.
- <strong>Subcutaneous implant</strong> - 65 mg - Every 12 months - Viadur implant for prostate cancer. Provides continuous release for one year. No longer widely available.
Half-Life
3 hours (free peptide); depot formulations maintain levels for 1-12 months.
Evidence Limits
Dosage entries are compiled from labels, published studies, and research-context references where available. For Leuprolide, the evidence grade is Level A, and the current research status is FDA Approved.
Safety Signals
- Tumor flare in first 1-2 weeks - anti-androgen cover recommended for prostate cancer
- Bone density monitoring recommended with use >6 months
- Increased cardiovascular and metabolic risk with long-term ADT
- Rare reports of pituitary apoplexy in patients with pituitary adenomas
- QT prolongation risk
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Advanced Prostate Cancer (Level A), Endometriosis Management (Level A), Central Precocious Puberty (Level A), and Uterine Fibroid Shrinkage (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Leuprolide Research Dosage: Published Protocol Reference." Last reviewed 2026-04-04. https://examinepeptides.com/answers/leuprolide-research-dosage/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.